InVitae Corp (NVTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

InVitae Corp (NVTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH443956D
  • |
  • Pages: 53
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Invitae Corp (Invitae), formerly Locus Development Inc, is a genetic information company which processes DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. The company's portfolio of diagnostic tests includes preimplantation and carrier screening for inherited disorders, miscarriage analysis, neurological disorders, metabolic disorders and pediatric and developmental disorders among others. Invitae specializes in offering exome analysis, panel and single gene genetic tests. It also provides proactive testing, genetic counseling resources, re-requistion testing, family variant testing and VUS resolution testing and clinical consult services. Invitae is headquartered in San Francisco, California, the US.

InVitae Corp (NVTA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

InVitae Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

InVitae Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

InVitae Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

InVitae Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

InVitae Corp, Medical Devices Deals, 2012 to YTD 2018 10

InVitae Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

InVitae Corp, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

InVitae Raises USD16 Million in Venture Financing 12

InVitae Raises USD 29.6 Million In Venture Financing 13

Partnerships 14

InVitae Expands Partnership with Sarepta Therapeutics 14

Invitae Enters into Agreement with Alnylam Pharma 15

Good Start Genetics Enters into Agreement with IviGen and iGenomix 16

Licensing Agreements 17

Good Start Genetics Enters into Licensing Agreement with Johns Hopkins University 17

Good Start Genetics Expands Licensing Agreement with Johns Hopkins University 18

Equity Offering 19

Invitae Prices Public Offering of Shares for USD50 Million 19

Invitae to Raise Funds through Public Offering of Shares 21

Invitae to Raise Funds through Public Offering of Shares 22

Invitae Raises USD73.5 Million in Private Placement of Shares and Preferred Shares 23

CombiMatrix Raises USD8 Million in Public Offering of Units 24

CombiMatrix Raises USD3.34 Million in Private Placement of Warrants 26

CombiMatrix Raise USD5 Million in Private Placement of Securities 28

CombiMatrix Completes Public Offering Of Units For USD 12 Million 30

CombiMatrix Completes Second Tranche Of Private Placement Of Preferred Shares For USD 1.2 Million 31

CombiMatrix Completes Private Placement Of Common Stock For USD 0.4 Million 32

CombiMatrix Completes Private Placement Of Units For USD 1.6 Million 33

Asset Transactions 34

Molecular Loop Acquires MIP-Based DNA Targeting Technology from Invitae 34

Acquisition 35

Invitae Acquires CombiMatrix for USD35 Million 35

InVitae Corp-Key Competitors 37

InVitae Corp-Key Employees 38

InVitae Corp-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Financial Announcements 40

Aug 07, 2018: Invitae reports more than 160% annual revenue growth driven by nearly 140% annual growth in volume in second quarter 2018 40

May 09, 2018: Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018 41

Feb 12, 2018: Invitae reports over 150% volume and over 170% revenue growth for 2017 43

Jan 08, 2018: Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018 45

Nov 06, 2017: Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017 46

Aug 07, 2017: Invitae Reports Second Quarter 2017 Results 49

Corporate Communications 51

Sep 11, 2018: Invitae names Chitra Nayak to its Board of Directors 51

Product News 52

Dec 05, 2017: Invitae to present findings at 2017 San Antonio Breast Cancer Symposium 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53

List of Figures

InVitae Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

InVitae Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

InVitae Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

InVitae Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

InVitae Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

InVitae Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

InVitae Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

InVitae Corp, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

InVitae Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

InVitae Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

InVitae Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

InVitae Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

InVitae Corp, Deals By Therapy Area, 2012 to YTD 2018 9

InVitae Corp, Medical Devices Deals, 2012 to YTD 2018 10

InVitae Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

InVitae Raises USD16 Million in Venture Financing 12

InVitae Raises USD 29.6 Million In Venture Financing 13

InVitae Expands Partnership with Sarepta Therapeutics 14

Invitae Enters into Agreement with Alnylam Pharma 15

Good Start Genetics Enters into Agreement with IviGen and iGenomix 16

Good Start Genetics Enters into Licensing Agreement with Johns Hopkins University 17

Good Start Genetics Expands Licensing Agreement with Johns Hopkins University 18

Invitae Prices Public Offering of Shares for USD50 Million 19

Invitae to Raise Funds through Public Offering of Shares 21

Invitae to Raise Funds through Public Offering of Shares 22

Invitae Raises USD73.5 Million in Private Placement of Shares and Preferred Shares 23

CombiMatrix Raises USD8 Million in Public Offering of Units 24

CombiMatrix Raises USD3.34 Million in Private Placement of Warrants 26

CombiMatrix Raise USD5 Million in Private Placement of Securities 28

CombiMatrix Completes Public Offering Of Units For USD 12 Million 30

CombiMatrix Completes Second Tranche Of Private Placement Of Preferred Shares For USD 1.2 Million 31

CombiMatrix Completes Private Placement Of Common Stock For USD 0.4 Million 32

CombiMatrix Completes Private Placement Of Units For USD 1.6 Million 33

Molecular Loop Acquires MIP-Based DNA Targeting Technology from Invitae 34

Invitae Acquires CombiMatrix for USD35 Million 35

InVitae Corp, Key Competitors 37

InVitae Corp, Key Employees 38

InVitae Corp, Subsidiaries 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

InVitae Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17745
Site License
USD 500 INR 35490
Corporate User License
USD 750 INR 53235

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com